Jonathan Havens of Saul Ewing Arnstein & Lehr LLP to talk about what the US FDA’s approval of GW Pharma’s Epidiolex CBD-derived product.
Havens described what will happen to Epidiolex now – including a possible rescheduling by the US Drug Enforcement Administration.
For more about Epidolex.
For more about Saul Ewing Arnstein & Lehr LLP.
For more about Jonathan Havens.
